Pradaxa Fails to Prevent Recurrence After Cryptogenic Stroke Pradaxa Fails to Prevent Recurrence After Cryptogenic Stroke

Dabigatran, sold under the brand name Pradaxa by Boehringer Ingelheim to prevent stroke in people with atrial fibrillation, is no more effective than aspirin for preventing a subsequent stroke in patients who have experienced a cryptogenic stroke.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news